L-carnitine on spirometry in hemodialysis

The effect of L-carnitine on ergo spirometry test results in chronic hemodialysis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161219031464N3

Enrollment

Registered

2019-08-29

Start date

2017-01-09

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relationship between L-carnitine and ergospirometric test results in chronic hemodialysis patients.

Interventions

Intervention 1: Intervention group1: Each patient receives two grams of l-carnitine tablets (2*1) daily for three months. Intervention 2: Control group: Each patient receives two tablets (placebo) dai

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Hemodialysis patients who have been on dialysis for at least three months Patients without active heart and lung disease

Exclusion criteria

Exclusion criteria: Inability to perform the ergospirometry test Active cardiac disease Active pulmonary disease

Design outcomes

Primary

Measure	Time frame
Change of ergo respiratory test after receiving the drug. Timepoint: Month 1 and 4. Method of measurement: Alteration of ergo spirometry test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Yassari

Shahid Beheshti University of Medical Sciences

fa.yassari@gmail.com+98 21 2712 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026